Amanote Research
Register
Sign In
Pnd105 - Multiple Sclerosis: The Map of Patient Access to Disease Modifying Treatments in Europe
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2071
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
HL Dakin
Publisher
Elsevier BV
Related search
Multiple Sclerosis Disease-Modifying Therapy and Pregnancy
Multiple Sclerosis
Neurology
Disease Modifying Treatments and Symptomatic Drugs for Cognitive Impairment in Multiple Sclerosis: Where Do We Stand?
Multiple Sclerosis and Demyelinating Disorders
Allergy
Immunology
Neurology
Correction To: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
CNS Drugs
Psychiatry
Mental Health
Neurology
Pharmacology
Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis
Neuropsychiatric Disease and Treatment
Psychiatry
Mental Health
Biological Psychiatry
Pnd120 - Treatment Decisions About First-Line Disease-Modifying Treatments (Dmts) in Relapsing Remitting Multiple Sclerosis: A Systematic Review of Patient Needs and Preferences
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the US
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Pnd131 - Patient Preferences for Different Modes and Frequency of Administration of Multiple Sclerosis Disease Modifying Therapies
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Archives of Neurology
